Combination therapy

Neurological Sciences

Volumn 27, Issue SUPPL. 5, 2006, Pages

  Martinelli, Vittorio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Combination therapy; Immunomodulatory agents; Immunosuppressive agents; Induction therapy; Multiple sclerosis

Indexed keywords

ALEMTUZUMAB; ANTIOXIDANT; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; FLUDARABINE; FOLIC ACID; GLATIRAMER; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; NEUROTROPHIC FACTOR; STEROID;

ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE CONTROL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; EVIDENCE BASED MEDICINE; GENE TARGETING; HEART DISEASE; HUMAN; INDIVIDUALIZATION; INFECTION; INFERTILITY; KIDNEY DYSFUNCTION; LEUKEMIA; LIVER DYSFUNCTION; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MULTIPLE SCLEROSIS; MUSCLE DISEASE; RISK BENEFIT ANALYSIS; SKIN ALLERGY; TERATOGENICITY; THROMBOSIS; THYROID DISEASE;

CLINICAL TRIALS, PHASE II; COMBINED MODALITY THERAPY; HUMANS; MULTIPLE SCLEROSIS;

EID: 33749137775     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-006-0692-x     Document Type: Article

References (17)

1. Goodin DS, Frohman EM, Garmany GP Jr et al (2002) Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58:169-178
2. Rudick RA, Lee J, Simon J et al (2004) Defining interferon beta response status in MS patients. Ann Neurol 56:548-555
3. Zaffaroni M (2005) Treatment optimization in multiple sclerosis. Neurol Sci 26:S187-S192
4. Barman TM, Kasper LH (2004) Novel approaches and cutting edge immunotherapies in multiple sclerosis. Front Biosci 9:2302-2322
5. Fox RJ, Ransohoff RM (2004) New directions in MS therapeutics: Vehicles of hope. Trends Immunol 25:632-636
6. Fontoura P, Garren H, Steinman L (2005) Antigen-specific therapies in multiple sclerosis: Going beyond proteins and peptides. Int Rev Immunol 24:415-446
7. Martinelli V, Comi G (2005) Induction versus escalation therapy. Neurol Sci 26:S193-S199
8. Multiple Sclerosis Therapy Consensus Group (2004) Escalating immunotherapy of multiple sclerosis: New aspects and practical application. J Neurol 251:1329-1339
9. Kappos L, Kuhle J, Gass A et al (2004) Alternatives to current disease-modifying treatment in MS: What do we need and what can we expect in the future? J Neurol 251[Suppl 5]:V57-V64
10. Weinstock-Guttman B, Bakshi R (2004) Combination therapy for multiple sclerosis. The treatment strategy of the future? CNS Drugs 18(12):777-792
11. Jeffery DR (2004) Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis. Neurology 63[Suppl 6]:s41-s46
12. Farrell R, Heaney D, Giovannoni G (2005) Emerging therapies in multiple sclerosis. Expert Opin Emerging Drugs 10:797-816
13. Martino G (2004) How the brain repairs itself: New therapeutic strategies in inflammatory and degenerative CNS disorders. Lancet Neurol 3:372-378
14. Comi G, Martino G (2006) MS treatment: New perspectives. Clin Neurol Neurosurg 108:339-345
15. Polman CH, O'Connor PW, Havrdova B et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing MS. N Engl J Med 354:899-910
16. Rudick RA, Sturt WH, Calabresi PA et al (2006) Natalizumab plus interferon beta 1a for relapsing multiple sclerosis. N Engl J Med 354:911-923
17. Yong VW, Wells J, Giuliani F et al (2004) The promise of Minocycline in neurology. Lancet Neurol 3:744-751